NasdaqGM:RYTMBiotechs
How Investors May Respond To Rhythm Pharmaceuticals (RYTM) Q2 Results And Early RM-718 Obesity Data
In August 2026, Rhythm Pharmaceuticals reported second-quarter 2026 results showing revenue of US$71.26 million versus US$48.50 million a year earlier, alongside a net loss of US$49.30 million and slightly improved loss per share.
The company also released early Phase 2 data for its weekly MC4R agonist RM-718 in acquired hypothalamic obesity, showing double-digit BMI reductions with fewer pigmentation issues, highlighting progress beyond its first-generation IMCIVREE franchise.
Now we’ll...